Table 2.
Characteristics of patients included in the improvement component
| Treatment group, (N) | Age1, mean (SD) | Ferritin2, mean (SD), median (IQR) | Gender3: males, n (%) |
|---|---|---|---|
| DFO (75) | 26.8 (5.7) | 2956 (2222), 2511 (1258–4302) | 51 (68.0) |
| DFP (35) | 31.0 (6.7) | 2252 (2573), 1151 (407–3025) | 21 (60.0) |
| Combination (61) | 30.1 (6.2) | 2927 (2386), 2135 (1023–3912) | 36 (59.0) |
| DFX (9) | 33.9 (6.2) | 2332 (1959), 1483 (1155–3009) | 5 (55.6) |
IQR, interquartile range; DFO, desferrioxamine; DFP, deferiprone; DFX, deferasirox.
1
anova: F-test = 8, P < 0.001. Significant comparisons (considering 0.05/6 = 0.008 as the confidence level after the Bonferroni correction): DFP vs. DFO (P-value = 0.002), Combination vs. DFO (P-value = 0.004), DFX vs. DFO (P-value = 0.006).
2
anova: F-test = 1, P = 0.37.
3
Fisher’s exact test: P = 0.65.